Lyell Immunopharma Inc (LYEL)

NASDAQ
5.44
-0.01(-0.18%)
After Hours
5.44
0.00(0.00%)
- Real-time Data
  • Volume:
    465,060
  • Bid/Ask:
    4.80/9.80
  • Day's Range:
    5.39 - 5.91

LYEL Overview

Prev. Close
5.45
Day's Range
5.39-5.91
Revenue
15.58M
Open
5.5
52 wk Range
4.95-19.84
EPS
-
Volume
465,060
Market Cap
1.31B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
573,670
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
240,471,497
Next Earnings Date
Mar 02, 2022
What is your sentiment on Lyell Immunopharma Inc?
or
Market is currently closed. Voting is open during market hours.

Lyell Immunopharma Inc Company Profile

Employees
189

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellNeutralStrong SellSell
SummaryStrong SellStrong SellSellStrong SellSell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.